In vivo CAR-T against solid-tumour antigens
If a lipid nanoparticle can make CAR-T cells inside the body for lymphoma, it could be redosed weekly against solid-tumour targets that autologous CAR-T cannot sustain.
Solid-tumour CAR-T fails partly from exhaustion and poor persistence of a single infused product. Transient, redosable in vivo CAR expression could deliver repeated waves of fresh effector cells.
Pages like this
not linked directly; found by shared links- CompanyUmoja Biopharma
Shares In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T, Manufacturing cost and time for living and radioactive medicines.
- CompanyInterius BioTherapeutics
Shares In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T, Manufacturing cost and time for living and radioactive medicines.
- PersonChangsong Qi
Shares Satricabtagene autoleucel, Claudin 18.2, Gastric & gastro-oesophageal junction cancer, CAR-T cell therapy.
- PersonLin Shen
Shares Satricabtagene autoleucel, Claudin 18.2, Gastric & gastro-oesophageal junction cancer, CAR-T cell therapy.
- RoadmapCell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR
Shares Glypican-3, Satricabtagene autoleucel, In vivo CAR-T, Claudin 18.2.
- CompanyOrna Therapeutics (Eli Lilly)
Shares In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T, Manufacturing cost and time for living and radioactive medicines.
- CompanyCARsgen Therapeutics
Shares Satricabtagene autoleucel, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
- PairingCLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression
Shares Satricabtagene autoleucel, Claudin 18.2, Gastric & gastro-oesophageal junction cancer.